C30 | LATE BREAKING ABSTRACTS IN DISEASE TREATMENT AND CLINICAL OUTCOMES
Late Breaking Poster Discussion Session: Tuesday, May 20, 8:15 AM - 10:45 AM, Room 8 (Upper Level), San Diego Convention Center
Poster Viewing: 8:15-9:15, Discussion: 9:15-10:45
"Clinical Benefit Of Liposomal Amikacin For Inhalation As Assessed By The Cystic Fibrosis Questionnaire-Revised"
Improvements on- versus off-treatment were observed with LAI (Arikace) on the Respiratory Symptoms, Physical Functioning, Vitality, and Health scales; improvements were observed with TIS only on the Physical Functioning and Vitality scales.
Treatment Burden with TIS was greater on- versus off-treatment; there was no difference on- versus off-treatment with LAI (Arikace).
Conclusion: Once-daily LAI is generally safe and well tolerated. These data provide additional evidence of the benefit of LAI treatment using multiple outcome measures, and additional validity to the use of the CFQ-R instrument. The lower treatment burden with LAI is expected to improve patient compliance, and consequently, clinical outcome.